Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2023First federal award
$3.6MFederal grants as PI4 awards
0Patents grantedNone matched
19Papers170 citations
Federal awards and patents by year
AwardsPatents
4 awards · $3.6M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Sep 14, 2026 | NIH | SBIR Phase II Treatment of GM1 gangliosidosis CNS manifestations by AAV systemic expression of lectin-enhanced enzyme | $1.5M | BIOSTRATEGIES LC |
| Sep 15, 2025 | NIH | SBIR Phase II Treatment of GM1 gangliosidosis CNS manifestations by AAV systemic expression of lectin-enhanced enzyme | $1.5M | BIOSTRATEGIES LC |
| Sep 20, 2023 | NIH | SBIR Phase I Morquio A therapy integrating gene transfer with lectin-enhanced enzyme delivery to treat multisystemic clinical impairments of rare metabolic childhood diseases | $296K | BIOSTRATEGIES LC |
| Sep 20, 2023 | NIH | SBIR Phase I Morquio A therapy integrating gene transfer with lectin-enhanced enzyme delivery to treat multisystemic clinical impairments of rare metabolic childhood diseases | $296K | BIOSTRATEGIES LC |
1 patents as inventor
- US BIOSTRATEGIES LC—
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#475
Awards as PI#566
Patents#273
Companies
- BIOSTRATEGIES LCLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.